Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

  • Review
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

The relative success of cisplatin-based chemotherapy regimens for PDAC in clinical trials warrants a review of the literature to assess the cumulative results. This study aims to assess the efficacy of cisplatin-containing regimens for PDAC in terms of survival and response outcomes using a systematic review and proportional meta-analysis.

Methods

In this study, an electronic search was conducted on PubMed, Cochrane Library, Scopus, and Google Scholar to find relevant literature. The random effects model was used to assess pooled overall response rate, stable disease rate, progressive disease rate, 1-year overall survival rate, and their 95% CIs. Publication bias was assessed using funnel plot symmetry and the one-tailed Eggers’ test. In all cases, p-value < 0.05 was indicative of significant results. The review is registered with PROSPERO: CRD42023459243.

Results

A total of 34 studies consisting of 1599 patients were included in this review. All the included studies were of good quality. In total, 906 patients were male, and the median age of the patients was 58–69 years. Overall, 599 patients had cancer of the pancreatic head, 139 had cancer of the pancreatic body, and 102 patients had cancer of the pancreatic tail. The pooled risk ratios (RRs) revealed an overall response rate of 19.2% (95% CI, 14.6–24.2%), a stable disease rate of 42.3% (95% CI, 36.6–48.8), a 1-year overall survival rate of 40% (95% CI, 34.3–45.8), and progressive disease rate of 24.7% (95% CI, 18.8–31.2). Commonly reported adverse events were anemia, thrombocytopenia, abdominal adverse events, neutropenia, fatigue, leukopenia, alopecia, anorexia, mucositis, stomatitis, and hepatobiliary adverse events.

Conclusion

Cisplatin-containing regimens have shown moderate efficacy with significant improvement in overall survival at 1 year, stable disease rate, and progressive disease rate; however, only a small percentage of patients achieved an overall response rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4): e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851–62. https://doi.org/10.1001/jama.2021.13027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729–54. https://doi.org/10.1016/j.cell.2023.02.014.

    Article  CAS  PubMed  Google Scholar 

  4. Watanabe A, Abe T, Oshita A, Hanada K, Noriyuki T, Nakahara M. Delayed local recurrence of pancreatic adenosquamous cell carcinoma after curative surgery: a case report. Int J Surg Case Rep. 2022;1(100): 107735. https://doi.org/10.1016/j.ijscr.2022.107735.

    Article  Google Scholar 

  5. Mezencev R, Matyunina L, Wagner G, et al. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther. 2016;23:446–53. https://doi.org/10.1038/cgt.2016.71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Taieb J, Prager GW, Melisi D, Westphalen CB, D’Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020;5(1):e000587. https://doi.org/10.1136%2Fesmoopen-2019–000587.

  7. Berners-Price SJ. Activating platinum anticancer complexes with visible light. Angew Chem Int Ed Engl. 2011;50:804–5. https://doi.org/10.1002/anie.201004552.

    Article  CAS  PubMed  Google Scholar 

  8. Oliver GR, Sugar E, Laheru D, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Gastrointestinal Cancers Symposium. 2010;180. https://doi.org/10.1007/s00280-015-2788-6.

  9. Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The lancet Gastroenterology & hepatology. 2018;3(10):691–7. https://doi.org/10.1016/S2468-1253(18)30196-1.

    Article  Google Scholar 

  10. Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D’Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b/2 pilot clinical trial. JAMA Oncol. 2020;6(1):125–32. https://doi.org/10.1001/jamaoncol.2019.3394.

    Article  PubMed  Google Scholar 

  11. O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard, H, Golan T, Segal, A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, … Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124(7):1374–82. https://doi.org/10.1002/cncr.31218.

  12. Lee KH, Chie EK, Im SA, Kim JH, Kwon J, Han SW, Oh DY, Jang JY, Kim JS, Kim TY, Bang YJ, Kim SW, Ha SW. Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine in patients with resected pancreatic cancer. Cancer Res Treat. 2021;53(4):1096–103. https://doi.org/10.4143/crt.2020.928.

    Article  CAS  PubMed  Google Scholar 

  13. Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM. A phase II study of biweekly cisplatin, fixed-dose-rate gemcitabine and infusional 5-fluorouracil in patients with metastatic pancreatic and biliary cancers. Am J Clin Oncol. 2018;41(2):128–32. https://doi.org/10.1097/COC.0000000000000240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, Peiffert D, Mornex F, Abbas M, Boige V, Pignon JP, Conroy T, Cellier P, Juzyna B, Viret F. Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014;46(10):950–5. https://doi.org/10.1016/j.dld.2014.06.006.

    Article  CAS  PubMed  Google Scholar 

  15. Chao Y, Wu CY, Wang JP, Lee RC, Lee WP, Li CP. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2013;72(3):637–42. https://doi.org/10.1007/s00280-013-2239-1.

    Article  CAS  PubMed  Google Scholar 

  16. Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2012;30(6):2371–6. https://doi.org/10.1007/s10637-012-9792-z.

    Article  CAS  PubMed  Google Scholar 

  17. Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012;19(7):2256–63. https://doi.org/10.1245/s10434-011-2205-2.

    Article  PubMed  Google Scholar 

  18. Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2012;70(3):381–9. https://doi.org/10.1007/s00280-012-1918-7.

    Article  CAS  PubMed  Google Scholar 

  19. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF, Francophone F, de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010;59(11):1527–34. https://doi.org/10.1136/gut.2010.216135.

    Article  CAS  PubMed  Google Scholar 

  20. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O’Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW, American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011;22(2):348–54. https://doi.org/10.1093/annonc/mdq384.

    Article  CAS  PubMed  Google Scholar 

  21. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92. https://doi.org/10.1002/jso.21527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, … Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28(10):1645–51. https://doi.org/10.1200/JCO.2009.25.4433.

    Article  CAS  PubMed  Google Scholar 

  23. Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer–a multi-centre randomised phase II study. Br J Cancer. 2009;101(11):1853–9. https://doi.org/10.1038/sj.bjc.6605420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(33):5506–12. https://doi.org/10.1200/JCO.2009.22.1309.

    Article  CAS  PubMed  Google Scholar 

  25. Ina S, Tani M, Kawai M, Hirono S, Miyazawa M, Nishioka R, Fujita Y, Yamaue H. Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer. Anticancer Res. 2008;28(4C):2373–7.

    CAS  PubMed  Google Scholar 

  26. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(15):2526–31. https://doi.org/10.1200/JCO.2007.15.5556.

    Article  CAS  PubMed  Google Scholar 

  27. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–9. https://doi.org/10.1093/annonc/mdn281.

    Article  CAS  PubMed  Google Scholar 

  28. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Moore DF Jr, Alberts SR. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the north central cancer treatment group phase ii study N9942. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(18):2567–72. https://doi.org/10.1200/JCO.2006.10.2111.

    Article  CAS  PubMed  Google Scholar 

  29. Ueno H, Okusaka T, Ikeda M, Morizane C, Ogura T, Hagihara A, Tanaka T. Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. Jpn J Clin Oncol. 2007;37(7):515–20. https://doi.org/10.1093/jjco/hym060.

    Article  PubMed  Google Scholar 

  30. Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs. 2007;18(3):263–71. https://doi.org/10.1097/CAD.0b013e3280121334.

    Article  CAS  PubMed  Google Scholar 

  31. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):809–16. https://doi.org/10.1016/j.ijrobp.2007.01.005.

    Article  CAS  PubMed  Google Scholar 

  32. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(24):3946–52. https://doi.org/10.1200/JCO.2005.05.1490.

    Article  CAS  PubMed  Google Scholar 

  33. Bang S, Jeon TJ, Kim MH, Park JY, Park SW, Chung JB, Song SY. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Pancreatology. 2006;6(6):635–41. https://doi.org/10.1159/000097784.

    Article  CAS  PubMed  Google Scholar 

  34. Feliu J, Sáenz JG, Jaráiz AR, Castañón C, Cruz M, Fonseca E, Lomas M, Castro J, Jara C, Casado E, León A, Barón MG. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. Cancer Chemother Pharmacol. 2006;58(4):419–26. https://doi.org/10.1007/s00280-005-0167-4.

    Article  CAS  PubMed  Google Scholar 

  35. Clayton AJ, Mansoor AW, Jones ET, Hawkins RE, Saunders MP, Swindell R, Valle JW. A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas. 2006;32(1):51–7. https://doi.org/10.1097/01.mpa.0000188306.67420.0f.

    Article  CAS  PubMed  Google Scholar 

  36. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14(7):2088–96. https://doi.org/10.1245/s10434-007-9384-x.

    Article  PubMed  Google Scholar 

  37. Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP, … European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European organisation for research and treatment of cancer gastrointestinal group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(36):9250–6. https://doi.org/10.1200/JCO.2005.02.1980.

    Article  CAS  PubMed  Google Scholar 

  38. Kosuge T, Kiuchi T, Mukai K, Kakizoe T, Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36(3):159–65. https://doi.org/10.1093/jjco/hyi234.

    Article  PubMed  Google Scholar 

  39. Wilkowski R, Thoma M, Dühmke E, Rau HG, Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2004;58(3):768–72. https://doi.org/10.1016/j.ijrobp.2003.07.002.

    Article  CAS  PubMed  Google Scholar 

  40. El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, Philip PA. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23(6):583–90. https://doi.org/10.1007/s10637-005-1028-z.

    Article  CAS  PubMed  Google Scholar 

  41. Mornex F, Girard N, Scoazec JY, Bossard N, Ychou M, Smith D, Seitz JF, Valette PJ, Roy P, Rouanet P, Ducreux M, Partensky C. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97–04 phase II trial. Int J Radiat Oncol Biol Phys. 2006;65(5):1471–8. https://doi.org/10.1016/j.ijrobp.2006.02.054.

    Article  CAS  PubMed  Google Scholar 

  42. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Study quality assessment tools | NHLBI, NIH [Internet]. NHLBI, NIH. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 20 Oct 2023.

  44. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A, Tanaka M. Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas. 2012;41(7):985–92. https://doi.org/10.1097/MPA.0b013e318258055c.

    Article  PubMed  Google Scholar 

  45. Tabarraee M, Rezaee A, Abolghasemi S, Ghadiany M, Ardakani MT, Mahdizadeh M, Hamidi N, Ghasemi K. Assessment of effectiveness and adverse effect of new combination chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma. Int J Hematol Oncol Stem Cell Res. 2023;17(3):194. https://doi.org/10.18502/ijhoscr.v17i3.13309.

  46. Mineur L, Plat F, Desseigne F, Deplanque G, Belkacemi M, Moureau-Zabotto L, Beyrne CD, Jalali K, Obled S, Smith D, Vazquez L. NESC multicenter phase II trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU+ lenograstim) followed by chemoradiation (CRT) based 5FU and oxaliplatin and surgery. Cancer Res Treat. 2023. https://doi.org/10.4143/crt.2023.812.

    Article  PubMed  Google Scholar 

  47. Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:471. https://doi.org/10.1186/1471-2407-14-471.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Huang D, Fang J, Luo G. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer. J Cancer Res Ther. 2016;12(Supplement):104–8. https://doi.org/10.4103/0973-1482.191616.

    Article  PubMed  Google Scholar 

  49. Ouyang G, Liu Z, Huang S, Li Q, Xiong L, Miao X, Wen Y. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World journal of surgical oncology. 2016;14:59. https://doi.org/10.1186/s12957-016-0813-9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, … Lehmann K. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Annals of Surgical Oncology. 2023;30(7):4417–28. https://doi.org/10.1245/s10434-023-13353-2.

  51. Aydh A, Sari Motlagh R, Alamri A, Yanagisawa T, Ayed A, Rajwa P, Laukhtina E, Alasiri SM, Kawada T, Mostafai H, Ayidh A. Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes. World J Urol. 2023;22:1. https://doi.org/10.1007%2Fs00345–023–04478-w.

  52. Correa-Morales JE, Giraldo-Moreno S, Mantilla-Manosalva N, Cuellar-Valencia L, Bedoya-Munoz LJ, Iriarte-Aristizábal MF, Quintero-Munoz E, Zuluaga-Liberato AM. Prevention and treatment of platinum ototoxicity in adults: a systematic review. 2023;49(1):1–15. https://doi.org/10.1111/coa.14106.

  53. Burns CV, Edwin SB, Szpunar S, Forman J. Cisplatin‐induced nephrotoxicity in an outpatient setting. Pharmacotherapy: the journal of human pharmacology and drug therapy. 2021;41(2):184–90. https://doi.org/10.1002/phar.2500.

  54. Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38(3):259–65. https://doi.org/10.1097/COC.0b013e3182940ff9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Services Institute of Medical Sciences, Lahore, 54000, Pakistan

    Obaid Ur Rehman, Eeshal Fatima, Habiba Imran & Hadia Mehboob

  2. Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan

    Zain Ali Nadeem

  3. University of Warmia and Mazury, Olszytn, Poland

    Arish Azeem

  4. Liaquat National Hospital and Medical College, Karachi, Pakistan

    Jatin Motwani

  5. Karachi Institute of Medical Sciences, CMH Malir, Karachi, Pakistan

    Alishba Khan

  6. Texas Tech University Health Sciences Center El Paso/Transmountain, El Paso, TX, USA

    Omer Usman

Authors
  1. Obaid Ur Rehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eeshal Fatima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zain Ali Nadeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arish Azeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jatin Motwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Habiba Imran
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hadia Mehboob
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alishba Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Omer Usman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Obaid Ur Rehman: writing—original draft, conceptualization, data analysis, and methodology; Eeshal Fatima: writing—original draft; Zain Ali Nadeem: writing—original draft and data analysis; Arish Azeem: writing—original draft; Jatin Motwani: writing—original draft; Habiba Imran: writing—original draft; Hadia Mehboob: writing—original draft; Alishba Khan: writing—original draft; Omer Usman: writing—review and editing.

Corresponding author

Correspondence to Obaid Ur Rehman.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 748 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rehman, O.U., Fatima, E., Nadeem, Z.A. et al. Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. J Gastrointest Canc (2024). https://doi.org/10.1007/s12029-024-01025-7

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12029-024-01025-7

Keywords

Search

Navigation